Eckert & Ziegler BEBIG: Full-Year 2012 Results, Continued profitability

Seneffe - Belgium, March 29, 2013 - Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) announced today its consolidated results for the year ending December 31, 2012.

A summary report including the milestones of 2012 and a selection of consolidated key figures for the twelve months ending December 31, 2012 can be downloaded at:

http://www.bebig.eu/home/investor-relations/financial-reports/interim-results.html

Sales for 2012 reached 31.8 million EUR, compared to 30.4 million EUR in 2011, showing an increase of 4.5%. The main components were income generated by the sales of permanent brachytherapy I-125 radiotherapeutic implants, as well as income from temporary brachytherapy equipment, i.e., HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources (also called "afterloaders").

Operating results reached 5.3 million EUR for the full year 2012, compared to 5.1 million EUR in 2011, showing an increase of 3.9%. Earnings before interest and taxes (EBIT) reached 5.2 million EUR in 2012, versus 5.0 million EUR in 2011, showing an increase of 4.0%.

Cash amounted to 3.3 million EUR at the end of December 2012, versus 5.1 million EUR in December 2011. The equity-to-asset ratio stood at 70.3% at the end of December 2011.

Shareholders Calendar:
Interim Statement 1Q-2013: Friday, May 3, 2013
Annual General Meeting: Thursday, June 13, 2013 (11:30 a.m.)
Half-Year Results 2013: Thursday, August 15, 2013
Interim Statement 3Q-2013: Friday, November 8, 2013

The results and trading updates will be published before market opens on the respective dates.

Eckert & Ziegler BEBIG
...Contributing to saving lives!

Eckert & Ziegler BEBIG is a European-based group, active in the medical device sector of the healthcare industry.

Its core business is the treatment of cancer by brachytherapy, a special form of radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and is headquartered in Belgium. It has a production facility in Germany and subsidiaries throughout Europe, as well as in India and in Brazil. Eckert & Ziegler BEBIG has also established a worldwide network of distributors and agents to support its product line.

The company`s products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.

Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB).

Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.eu




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE

HUG#1688758
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here